Hyperion Therapeutics Inc. Reaches New 12-Month High at $29.53 (HPTX)
Hyperion Therapeutics (NASDAQ:HPTX)’s share price reached a new 52-week high during mid-day trading on Tuesday, StockRatingsNetwork reports. The stock traded as high as $29.53 and last traded at $28.87, with a volume of 79,899 shares traded. The stock had previously closed at $28.44.
A number of analysts have recently weighed in on HPTX shares. Analysts at Leerink Swann cut their price target on shares of Hyperion Therapeutics from $33.00 to $32.00 in a research note to investors on Wednesday, November 13th. They now have an “outperform” rating on the stock. Analysts at Cowen and Company cut their price target on shares of Hyperion Therapeutics from $32.00 to $30.00 in a research note to investors on Wednesday, November 13th. They now have an “outperform” rating on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. Hyperion Therapeutics presently has a consensus rating of “Buy” and an average target price of $32.04.
In other Hyperion Therapeutics news, SVP Christine Nash sold 10,000 shares of Hyperion Therapeutics stock on the open market in a transaction that occurred on Tuesday, January 14th. The stock was sold at an average price of $24.09, for a total transaction of $240,900.00. Following the completion of the transaction, the senior vice president now directly owns 5,098 shares of the company’s stock, valued at approximately $122,811. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Hyperion Therapeutics has a 1-year low of $14.04 and a 1-year high of $29.53. The stock has a 50-day moving average of $22.97 and a 200-day moving average of $24.31. The company has a market cap of $580.7 million and a P/E ratio of 70.22.
Hyperion Therapeutics (NASDAQ:HPTX) last released its earnings data on Tuesday, November 12th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.18. Analysts expect that Hyperion Therapeutics will post $0.79 EPS for the current fiscal year.
Hyperion Therapeutics, Inc (NASDAQ:HPTX)is a development-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.